Danish Pharmacovigilance Update, 23 May 2013

17 June 2013

In this issue of Danish Pharmacovigilance Update:

  • Cases of necrotising fasciitis associated with the use of bevacizumab (Avastin®) (front page)
  • Tolvaptan (Samsca®) and potential risk of hepatic injury (p 2)
  • Liver fibrosis reported as a potential adverse reaction from the use of methotrexate (p 3)
  • The European Medicines Agency (EMA) has started a review of the efficacy and risks of combined use of renin-angiotensin system(RAS)-blocking agents (p 4)

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.